Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Obstet Gynaecol ; 36(3): 410-5, 2016.
Article in English | MEDLINE | ID: mdl-26492359

ABSTRACT

117 women with severe pelvic organ prolapse (POP; stage > 2) were enrolled to elucidate a 24-month outcome of POP surgery, using conventional or mesh repair with 3 techniques. 59 patients underwent conventional repair and 58 underwent mesh repair. Two types of mesh were used: a trocar-guided transobturator polypropylene (Avaulta, Bard Inc.) and a porcine dermis mesh (Pelvisoft, Bard Inc.). Women with recurrences, who underwent previous unsuccessful conventional repair, were randomised. Primary outcome was the evaluation of anatomic failures (prolapse stage > 1) in treated and untreated compartments. Anatomic failure was observed in 11 of 58 patients (19%; CI 8.9-29) in the mesh group and in 16 of 59 patients (27.1%; p value = 0.3) in the conventional group. 9 of 11 failures in the mesh group (15.5%; CI 6.2-24.8) were observed in the untreated compartment (de novo recurrences), 14.3% in Pelvisoft and 16.7% in Avaulta arm, while only 1 recurrence in the untreated compartment (1.7%) was observed in the conventional group (odds ratio 10.6, p = 0.03).


Subject(s)
Gynecologic Surgical Procedures/instrumentation , Pelvic Organ Prolapse/surgery , Aged , Female , Humans , Middle Aged , Recurrence , Surgical Mesh
4.
Minerva Ginecol ; 67(1): 7-12, 2015 Feb.
Article in English | MEDLINE | ID: mdl-24867068

ABSTRACT

AIM: The aim of this paper was to evaluate the hypothesis that pretreatment with dehydroepiandrosterone (DEHA) may improve the result on in vitro fertilization (IVF) and the pregnancy outcome among infertile women with normal ovarian reserve. METHODS: Double-blind, randomized, placebo-controlled study; 52 infertile patients received the long protocol IVF. Patients in Group 1, received 75 mg of DHEA once a day, 8 weeks before starting the IVF cycle and during treatment; control group (Group 2) received placebo. The primary endpoint was pregnancy, live birth and miscarriage rates, secondary endpoint was standard IVF parameters such us stimulation duration (hCG day), E2 on HCG-day, endometrial thickness, number of retrieved oocytes, metaphase II oocytes, embryos transferred and score of leading embryos transferred. RESULTS: Patients in the DHEA group had a significantly higher live birth rate compared with controls (P<0.05). Miscarriage rate was higher in control group (P<0.05). CONCLUSION: DHEA supplementation could have a beneficial effect on IVF outcome in infertile women with normal ovarian reserve.


Subject(s)
Dehydroepiandrosterone/administration & dosage , Fertilization in Vitro/methods , Infertility, Female , Pregnancy Outcome , Abortion, Spontaneous/epidemiology , Adult , Chorionic Gonadotropin/blood , Double-Blind Method , Female , Humans , Oocytes/metabolism , Ovarian Reserve/physiology , Pregnancy , Pregnancy Rate , Prospective Studies , Treatment Outcome
6.
J Obstet Gynaecol ; 34(1): 93-5, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24359066

ABSTRACT

We report the efficacy of a minimally invasive approach of the multidose protocol with methotrexate (MTX) in the management of three cases of interstitial pregnancy (IP), with elevated serum ß-hCG in two cases. New considerations and management strategies are discussed. Successful termination of IP and in one case, a subsequent successful pregnancy, was achieved. The process led to the development of an enhanced understanding of diagnostic modalities and their limitations, with regard to the particular entities under discussion. We also focused attention on pivotal points and anatomical features in the management of this dangerous occurrence. Long-term results with careful follow-up were analysed by instrumental procedure. This hazardous type of ectopic pregnancy can be managed with systemic administration of MTX, also in patients with elevated ß-hCG values. The present report underlines that an integrated approach in early diagnosis, multidose treatment and close follow-up, are essential forms of medical management.


Subject(s)
Abortifacient Agents, Nonsteroidal/therapeutic use , Methotrexate/therapeutic use , Pregnancy, Ectopic/drug therapy , Adult , Female , Humans , Pregnancy
SELECTION OF CITATIONS
SEARCH DETAIL
...